scholarly journals Complementary use of topical bitter melon for atopic dermatitis

2012 ◽  
Vol 2 (1) ◽  
pp. 7 ◽  
Author(s):  
Dai Park ◽  
Nguyen P. Tran ◽  
Jerald M. Duncan ◽  
D. Betty Lew

<em>Momordica charantia</em> (bitter melon) is popular in systems of traditional medicine to treat a variety of diseases including atopic dermatitis, which is an inflammatory, chronically relapsing skin disorder characterized by dry, scaly, pruritic skin. While there is growing community interest in adopting bitter melon as a complementary medicine, there are no clinical studies looking at its use for atopic dermatitis. Here we report a case of a 6-yearold female with severe refractory atopic dermatitis that responded to treatment with topical bitter melon in an open half-side comparison trial.

2015 ◽  
Vol 44 (11) ◽  
pp. 1637-1644 ◽  
Author(s):  
Jeong-Han Moon ◽  
Dong-Won Choi ◽  
Seong-Eun Kim ◽  
Ji-Hoon Seomoon ◽  
Su-Young Hong ◽  
...  

2021 ◽  
pp. 1-4
Author(s):  
Maurizio Romagnuolo ◽  
Mauro Barbareschi ◽  
Simona Tavecchio ◽  
Luisa Angileri ◽  
Silvia Mariel Ferrucci

Alopecia areata (AA), an autoimmune disease with a relapsing-remitting course, represents the second cause of non­scarring alopecia worldwide and is associated with several comorbidities, notably atopic dermatitis (AD). In particular, AD is related to its more severe forms alopecia totalis (AT) and alopecia universalis (AU) [Nat Rev Dis Primers. 2017;3:17011]. Considering that AA has been classified as T helper 1-driven disease, whereas AD is the prototypical T helper 2 (Th2)-driven skin disorder, recent studies suggest that these forms may underlie a different chemokine expression resulting in a Th2 skewing as a key pathomechanism that could explain this association [JAMA Dermatol. 2015 May;151(5):522–8]. Several reports showed that dupilumab, a fully human monoclonal antibody targeting the interleukin 4α receptor and thus downregulating Th2 response, led to an improvement of AA associated with AD; most of these patients were females with AT or AU, early-onset AD, and atopic comorbidities [Exp Dermatol. 2020 Aug;29(8):726–32]. We report here a case to further support this hypothesis.


2016 ◽  
Vol 15 (3) ◽  
pp. 376-389 ◽  
Author(s):  
Mingo M. H. Yung ◽  
Fiona A. Ross ◽  
D. Grahame Hardie ◽  
Thomas H. Y. Leung ◽  
Jinbiao Zhan ◽  
...  

2012 ◽  
Vol 135 (3) ◽  
pp. 976-984 ◽  
Author(s):  
Chin Hsu ◽  
Tsung-Hsien Tsai ◽  
You-Yi Li ◽  
Wen-Huey Wu ◽  
Ching-Jang Huang ◽  
...  

2018 ◽  
Vol 17 (1) ◽  
Author(s):  
Yanmei Zeng ◽  
Meiping Guan ◽  
Chenzhong Li ◽  
Lingling Xu ◽  
Zhongji Zheng ◽  
...  

2011 ◽  
Vol 3 (2) ◽  
Author(s):  
Yi Tang ◽  
Ji Liu ◽  
Bin Liu ◽  
Xiaomei Li ◽  
Juan Li ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document